FilingReader Intelligence
Wantai Bio's nine-valent HPV vaccine approved in China
June 9, 2025 at 09:40 PM UTC•By FilingReader AI
Beijing Wantai Biological Pharmacy Enterprise (SSE:603392) has announced that its subsidiary, Xiamen Wantai Canghai Bio-technology, has received approval for its nine-valent Human Papillomavirus (HPV) vaccine, named "Cecolin 9". This vaccine, produced using E. coli, covers seven high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and two low-risk types (6, 11). Dosing is two shots for ages 9-17 and three shots for ages 18-45.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:603392•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Wantai Biological Pharmacy Enterprise publishes news
Free account required • Unsubscribe anytime